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A B S T R A C T
Purpose: There is now extensive evidence to support the involvement of inﬂammation in the course of
epileptic seizures. Seizure-induced changes in serum IL-1b, IL-6 and IL-1Ra levels are reported in several
studies. Serum cytokine levels may also be disturbed in inter-ictal period due to seizure activity.
Methods: Twenty-one patients (12 women; mean age 35  12.3) with temporal lobe epilepsy (TLE), 17
patients (8 women; mean age 31.8  10.4) with extra-temporal lobe epilepsy (XLE) and 20 normal controls
(10 women; mean age 35.6  8.8) were included in the study. Serum levels of IL-1b, IL-6 and IL-1Ra of the
TLE, XLE groups in inter-ictal period and of the normal control group were compared.
Results: All three cytokine levels are found to be signiﬁcantly elevated in epilepsy patients when
compared to controls (p < 0.05). In TLE group, IL-1b serum levels were signiﬁcantly higher than in the
XLE group (p < 0001).
Conclusion: The major ﬁndings in our study were increased levels of IL-1b, IL-6 and IL-1Ra in epileptic
patients and high levels of IL-1b in TLE group. Our results support the existence of a chronic
inﬂammatory state in epileptic patients.
 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eiz1. Introduction
Recent studies suggested involvement of inﬂammation and
inﬂammatory cytokines in the pathogenesis and the course of
epilepsy. Among different inﬂammatory cytokines studied such as
TNF-a and IL-17A, it has been IL-6, IL-1b and IL-1Ra which have
attracted most attention in clinical studies [1–4].
In 1998, Peltola et al. reported for the ﬁrst time that IL-6 plasma
and cerebrospinal ﬂuid levels of patients with recent seizures
(<72 h) were higher than seizure-free patients and controls [5].
Following studies investigated plasma levels of IL-6, IL-1b and IL-
1Ra after epileptic seizures. Although seizure induced IL-6 increase
in plasma is almost invariable, changes in IL-1Ra levels after
epileptic seizures are less prominent and IL-1b levels are found to
be increased but also to be unchanged in some studies probably
due to local and transient production of the cytokine in low
quantities [6–9]. Some publications on cytokine and epilepsy
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levels, specially IL-6 serum levels, than extra-temporal lobe
epilepsy (XLE) [8,10]. These studies demonstrated that seizures
are associated with activation of a cytokine cascade caused by
neuronal excitation. Several reports indicate that IL-1b, IL-6 and
IL-1Ra may also have patho-physiological relevance to epilepsy. In
experimental models the blockade of the IL-1b biosynthesis
prevented the occurrence of epileptic EEG activity and the injection
of exogenous IL-1b resulted in hippocampal neuro-degeneration.
The effects of IL-1b are inhibited by IL-1Ra [11,12]. Chronic
overexpression of IL-6 is associated with the development of
spontaneous seizures but in contrast the lack of IL-6 increases
seizure susceptibility [13,14].
In the present study we investigated elevated serum IL-1b, IL-1Ra
and IL-6 levels in epileptic patients which cannot be explained by post-
ictal cytokine increases and which may reﬂect pathologically high
basal cytokine levels contributing to the pathogenesis in epilepsy.
We aimed to study the IL-1b, IL-1Ra and IL-6 levels in epileptic
patients during interictal state and normal controls. Because of the
selective temporal lobe degeneration caused by IL-1b and the
higher post-ictal cytokine release reported in TLE, we focused on
differences in cytokine proﬁles of the epileptic syndromes of
temporal and extra-temporal origin.served.
Table 1
Demographic and clinical features of the patients.
TLE
n = 21
XLE
n = 17
Age (years)a 35  12.3 [19–59] 31.8  10.4 [20–54]
Female/male 12/9 8/9
Disease yearsa 19.8  12.9 [2–47] 12.8  8.9 [3–30]
Age at disease onseta 15.2  9.9 [1–40] 19.5  16.8 [1–59]
Seizure/montha 3.1  5.1 [0.1–20] 1.8  2.6 [0.1–8]
Cranial MRI
Normal 11 17
Unilateral HS (right/left) 3/5 –
Bilateral HS 2 –
Laterality
Right/left/could not be
determined
4/12/5 7/6/4
EEG
Normal 2 –
Unilateral temporal EA
(right/left)
4/12 –
Bilateral temporal EA 3 –
Unilateral frontal EA
(right/left)
– 5/5
Bilateral frontal EA – 4
Other focal EEG
abnormalities
– 3
Generalized EA – –
Treatment
Monotherapy 7 9
2 AED 7 5
3 AED 7 3
AED
Valproic acid 15 7
Carbamazepine 9 9
Lamotrigine 11 8
Levetirasetam 11 2
Oxcarbazepine 3 1
Topiramate 2 1
Phenytoin 1 1
Pregabaline 2 –
Clonazepam 1 –
Zonisamide 1 –
TLE: temporal lobe epilepsy, XLE: extra-temporal lobe epilepsy, MRI: magnetic
resonance imaging, HS: hippocampal sclerosis, EEG: electroencephalography, EA:
epileptiform abnormality, AED: anti-epileptic drug.
a Values in mean  SD.
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Thirty-eight patients with refractory localization-related epi-
lepsy admitted to the video-electroencephalography (EEG) labo-
ratory of the Izmir Tepecik Educational and Research Hospital and
20 normal controls (10 women; mean age 35.6  8.8 [22–53]) were
included in the study. The Ethics Committee of the hospital approved
the study, and all patients gave their written informed consent.
All patients underwent ﬁve days of video-EEG monitoring.
Throughout the ﬁve days inpatient monitoring period, blood
samples were collected from those patients who did not have an
epileptic seizure within the last 72 h. Patients with concomitant
neoplasm, infectious or inﬂammatory diseases, hepatic or renal
insufﬁciency, recent trauma, surgery or immune-modulatory
treatment and with any central nervous system lesion other than
hippocampal sclerosis in cranial magnetic resonance imaging
(MRI) (obtained just before the inpatient period) were excluded.
The control group consisted of age and sex matched healthy
volunteers without any chronic diseases including obstructive
sleep apnea and acute cerebrovascular or cardiovascular event,
trauma or surgery.
Patients were divided into two groups: those with TLE and
those with XLE. The diagnosis of TLE and XLE was based on seizure
semiology, interictal and ictal EEG and/or video-EEG recordings,
and high resolution 1.5 T MRI of the brain [15].
Serum blood samples were immediately centrifuged
(3000 rpm, 4 8C) and frozen at 80 8C until further processing.
Cytokine levels were measured with sandwich ELISA (Enzyme
Linked Immunosorbent Assay) method by commercially available
assays (Human IL-1b Platinum ELISA and Human IL-16 High
Sensitivity ELISA, Bender MedSystems GmbH, Austria; Human
IL-1Ra Cytoscreen ELISA, Biosource, Belgium) according to the
manufacturer’s instructions. Serum levels of IL-1b, IL-6 and IL-1Ra
of the TLE, XLE and normal control groups were compared.
Statistical analysis was performed using the non-parametric
(less than 30 subjects in each study group) Kruskal–Wallis test
followed by Mann–Whitney U test. The correlations were analyzed
by using the Spearman’s test. A p-value of 0.05 was considered
signiﬁcant. SPSS version 22.0 was used.
3. Results
Demographical and clinical features of the patients are shown
in Table 1. TLE, XLE and normal control groups were similar
regarding age and sex. In patients with TLE, epileptic seizures were
started earlier and the seizures were more frequent but the
differences were not statistically signiﬁcant.
Serum cytokine levels are given in Table 2. In epileptic patients,
signiﬁcantly higher levels of IL-6, IL-1b and IL-1Ra than controls
were observed.
In TLE patients, we found signiﬁcantly higher serum IL-1b
levels than in XLE patients (1.36  0.93 vs 0.54  0.31, p = 0.001).
When TLE and XLE groups are compared separately to normal
controls, in TLE group both three cytokine levels were higher than
normal controls but in XLE group, only IL-1b and IL-1Ra levels
were signiﬁcantly higher.
IL1Ra/IL1b ratio was higher in normal controls and lower in TLE
patients but the difference was not signiﬁcant.
We did not ﬁnd a correlation between IL-6 levels and IL-1Ra as
well as IL-1Ra/IL-1b ratio in any of the study groups but IL-6 levels
were correlated with IL-1b (p = 0.003, R = 0.61) in TLE group.
There were not any differences between TLE patients with and
without mesial temporal sclerosis.
Serum cytokine levels were not correlated with disease years,
seizure frequencies and number of antiepileptic drugs used.4. Discussion
We found high IL-1b, IL-1Ra and IL-6 levels in epileptic patients.
There are several reports which are convergent with our study
results.
Hulkkonen et al. reported a trend toward elevated plasma levels
of IL-6 in patients with treatment resistant epilepsy [16]. Lehtima¨ki
et al. also showed a trend to increased basal IL-6 levels in epileptic
patients when compared to controls [9]. In the study of Sinha et al,
IL-1b and IL-6 levels of the epileptic patients in inter-ictal period
(n = 16) were higher than normal controls (n = 100) [17]. Lehtima¨ki
et al. found higher serum IL-6 levels in epileptic patients with
intellectual disability than the controls [18]. Inter-ictal serum IL-
1b levels were elevated in patients with epilepsy compared to
controls [4]. A recent study found interictal elevation of IL-6 but
not of IL-1b [1]. One of the causes of the high cytokine levels in
epileptic patients may be frequent seizures. Seizure-dependent
release of cytokines is related to the severity of the seizure and
lasts up to 24 h [10,19,25,26]. Central nervous system lesions such
as focal cortical dysplasia and glioneural tumors seen in epileptic
patients may be associated with the over-expression of IL-1b in
lesional or peri-lesional areas of chronic inﬂammation [20].
Table 2
IL-6, IL-1b, IL-1Ra levels of the patients and controls.
IL-6 IL-1b IL-1Ra IL-1Ra/IL-1b
TLE
Mean  SD 0.76  0.18* 1.36  0.93*,z 130.05  50.56* 196.42  371.21
Median 0.76 1.04 124.5 127.08
Range 0.47–1.11 0.04–3.34 61.43–234.63 32.8–1801.81
XLE
Mean  SD 0.68  0.36 0.54  0.31** 111.88  78.58** 240.39  125.86
Median 0.6 0.44 85.65 189.47
Range 0.47–2.02 0.11–1.05 47.31–351.21 81.66–460.48
TLE and XLE
Mean  SD 0.73  0.27y 0.99  0.83y 121.92  64.31y 216.09  265.34
Median 0.67 0.84 101.84 143.2
Range 0.47–2.02 0.04–3.34 47.31–351.21 32.80–1801.81
Normal control
Mean  SD 0.53  0.12 0.24  0.11 50.33  14.06 292.48  265.34
Median 0.49 0.25 44.87 209.48
Range 0.4–0.88 0.04–0.45 33.52–88.72 75.98–1291.05
Values given in pg/mL.
TLE: temporal lobe epilepsy, XLE: extra-temporal lobe epilepsy.
* TLE > normal controls: p < 0.001 for IL-6, IL-1b and IL-1Ra.
** XLE > normal controls: p = 0.001 for IL-1b and p = 0.005 for IL-1Ra.
y TLE and XLE > normal controls: p = 0.04 for IL-6, p < 0.001 for IL-1b and IL-1Ra.
z TLE > XLE: p = 0.001 for IL-1b.
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peripheral blood mononuclear cells to stimulation in epileptic
patients [1,16,21]. Such alteration in reactions of peripheral blood
mononuclear cells may cause a pro-inﬂammatory state leading to
the facilitation of epileptic seizures.
In our study, high IL-1b, IL-1Ra and IL-6 levels in epileptic
patients may not be explained by the seizure-induced cytokine
changes since patients were seizure free for at least 72 h, a
sufﬁciently long period for tested cytokines to return to baseline
levels [5,6]. We excluded patients with central nervous system
lesions other than mesial temporal sclerosis to rule out the effect of
the cytokine increase related to the neuro-degeneration. Although
an effect resulting from recurrent seizures cannot be totally
excluded, we think that high cytokine levels in epileptic patients
are the reﬂection of a trend toward chronic inﬂammatory state in
epilepsy. This observation is supported by experimental models,
showing that acute inﬂammation is associated with brain
excitability which may lead to long-lasting increased sensitivity
to seizures [22].
In addition to elevated levels of all three cytokines in epileptic
patients, IL-1b was signiﬁcantly higher in TLE patients than
XLE patients and normal controls and we founded the lowest
IL-1Ra/IL-1b ratio in TLE group. Because the difference in seizure
frequency was not signiﬁcant between two groups, we do not
believe that the high IL-1 b level observed in TLE may be solely
explained by the seizure frequency. Homozygosity for IL-1b gene
polymorphism is found to be more frequent in TLE patients with
hippocampal sclerosis than in TLE patients without hippocampal
sclerosis or normal controls [23]. This genotypic variation leads to
over-expression of the protein which may contribute to hippo-
campal damage in TLE. There have been other studies from
different ethnic populations supporting or contradicting the high
frequency of IL-1b polymorphism in TLE since then [24,25]. The
signiﬁcantly higher levels of IL-1b in our TLE patients may be
related to a genetic predisposition contributing to the pathogene-
sis of TLE. Unfortunately we were not able to compare TLE patients
with and without hippocampal sclerosis because of the small
number of patients. The low number of patients used could also
explain why we did not ﬁnd any correlation between serum
cytokine levels and disease years and seizure frequency.Because the three groups were similar in age and sex, we do not
believe that cytokine levels are affected by these factors. Likewise,
there is not a statistically signiﬁcant difference in disease years and
seizure frequency between TLE and XLE groups which may be the
cause of the high IL-1b levels in TLE group. Because of the limited
numbers of patients and the diversity in their medications, the
effect of each anti-epileptic drug in serum cytokine levels could not
be analyzed. Also some other factors which may contribute to the
changes in serum cytokine levels like the obesity and the stress due
to hospitalization cannot be excluded [26].
In conclusion, we suggest that the elevated inter-ictal serum
cytokine levels in epileptic patients point out the role of
inﬂammatory processes in triggering or sustaining the seizures.
This ﬁnding may have implications for future approaches targeting
systemic inﬂammation in the treatment of epilepsy.
Conﬂict of interest
None.
References
[1] Nowak M, Bauer S, Haag A, Cepok S, Todorova-Rudolph A, Tackenberg B, et al.
Interictal alterations of cytokines and leukocytes in patients with active
epilepsy. Brain Behav Immun 2011;25(3):423–8.
[2] Vezzani A, Baram TZ. New roles for interleukin-1beta in the mechanisms of
epilepsy. Epilepsy Curr 2007;7(2):45–50.
[3] Marchi N, Granata T, Janigro D. Inﬂammatory pathways of seizure disorders.
Trends Neurosci 2014;37(2):55–65.
[4] Mao LY, Ding J, Peng W-F, Ma Y, Zhang YH, Fan W, et al. Interictal interleukin-
17A levels are elevated and correlate with seizure severity of epilepsy patients.
Epilepsia 2013;54(9):142–5.
[5] Peltola J, Hurme M, Miettinen A, Kera¨nen T. Elevated levels of interleukin-6
may occur in cerebrospinal ﬂuid from patients with recent epileptic seizures.
Epilepsy Res 1998;31(2):129–33.
[6] Uludag IF, Bilgin S, Zorlu Y, Tuna G, Kirkali G. Interleukin-6, interleukin-1beta
and interleukin-1 receptor antagonist levels in epileptic seizures. Seizure
2013;22(6):457–61.
[7] Peltola J, Palmio J, Korhonen L, Suhonen J, Miettinen A, Hurme M, et al. Interleu-
kin-6 and Interleukin-1 receptor antagonist in cerebrospinal ﬂuid from patients
with recent tonic–clonic seizures. Epilepsy Res 2000;41(3):205–11.
[8] Alapirtti T, Rinta S, Hulkkonen J, Ma¨kinen R, Kera¨nen T, Peltola J. Interleukin-6,
interleukin-1 receptor antagonist and interleukin-1beta production in
patients with focal epilepsy: a video-EEG study. J Neurol Sci 2009;280
(1–2):94–7.
I.F. Uludag et al. / Seizure 26 (2015) 22–25 25[9] Lehtima¨ki K, Kera¨nen T, Palmio J, Ma¨kinen R, Hurme M, Honkaniemi J, et al.
Increased plasma levels of cytokines after seizures in localization-related
epilepsy. Acta Neurol Scand 2007;116(4):226–30.
[10] Bauer S, Cepok S, Todorova-Rudolph A, Nowak M, Ko¨ller M, Lorenz R, et al.
Etiology and site of temporal lobe epilepsy inﬂuence postictal cytokine
release. Epilepsy Res 2009;86(1):82–8.
[11] Akin D, Ravizza T, Maroso M, Carcak N, Eryigit T, Vanzulli I, et al. IL-1b is
induced in reactive astrocytes in the somatosensory cortex of rats with genetic
absence epilepsy at the onset of spike-and-wave discharges, and contributes
to their occurrence. Neurobiol Dis 2011;44:259–69.
[12] Depino A, Ferrari C, Pott Godoy M, Tarelli R, Pitossi F. Differential effects of
interleukin-1beta on neurotoxicity, cytokine induction and glial reaction in
speciﬁc brain regions. J Neuroimmunol 2005;168(1–2):96–110.
[13] Campbell I, Abraham C, Masliah E, Kemper P, Inglis J, Oldstone M, et al.
Neurologic disease induced in transgenic mice by cerebral overexpression
of interleukin 6. Proc Natl Acad Sci U S A 1993;90(21):10061–65.
[14] De Sarro G, Russo E, Ferrari G, Giuseppe B, Flocco M, Di Paola E, et al. Seizure
susceptibility to various convulsant stimuli of knockout interleukin-6 mice.
Pharmacol Biochem Behav 2004;77(4):761–6.
[15] Luders H, Acharya J, Baumgartner C, Benbadis S, Bleasel A, Burgess R, et al.
Semiological seizure classiﬁcation. Epilepsia 1998;39:1006–13.
[16] Hulkkonen J, Koskikallio E, Rainesalo S, Kera¨nen T, Hurma M, Peltola J. The
balance of inhibitory and excitatory cytokines is differently regulated in vivo
and in vitro among therapy resistant epilepsy patients. Epilepsy Res
2004;59(2):199–205.
[17] Sinha S, Patil S, Jayalekshmy V, Satishchandra P. Do cytokines have any role in
epilepsy? Epilepsy Res 2008;82(2):171–6.[18] Lehtima¨ki K, Liimatainen S, Peltola J, Arvio M. The serum level of interleukin-6
in patients with intellectual disability and refractory epilepsy. Epilepsy Res
2011;95(1–2):184–7.
[19] Lehtima¨ki K, Kera¨nen T, Palmio J, Peltola J. Levels of IL-1b and IL-1Ra in
cerebrospinal ﬂuid of human patients after single and prolonged seizures.
Neuroimmunomodulation 2010;17:19–22.
[20] Ravizza T, Boer K, Redeker S, Spliet W, van Rijen P, Troost D, et al. The IL-1beta
system in epilepsy-associated malformations of cortical development. Neu-
robiol Dis 2006;24(1):128–43.
[21] Paciﬁci R, Paris L, Di Carlo S, Bacosi A, Pichini S, Zuccaro P. Cytokine production
in blood mononuclear cells from epileptic patients. Epilepsia 1995;35(4):
384–7.
[22] Riazi K, Galic M, Pittman Q. Contributions of peripheral inﬂammation to
seizure susceptibility: cytokines and brain excitability. Epilepsy Res 2010;89:
34–42.
[23] Kanemoto K, Kawasaki J, Miyamoto T, Obayashi H, Nishimura M. Interleukin
(IL)-1b IL-1a, and IL-1 receptor antagonist gene polymorphisms in patients
with temporal lobe epilepsy. Ann Neurol 2010;47:571–4.
[24] Buono R, Ferraro T, O’Connor MJ, Sperling MR, Ryan SG, Scattergood T, et al.
Lack of association between an interleukin-1beta (IL-1b) gene variation and
refractory temporal lobe epilepsy. Epilepsia 2001;42(6):782–4.
[25] Ozkara C, Uzan M, Tanriverdi T, Baykara O, Ekinci B, Yeni N, et al. Lack of
association between IL-1beta/alpha gene polymorphisms and temporal lobe
epilepsy with hippocampal sclerosis. Seizure 2006;15(5):288–91.
[26] Testelmans D, Tamisier R, Barone-Rochette G, Baguet JP, Roux-Lombard P,
Pe´pin JL, et al. Proﬁle of circulating cytokines: impact of OSA, obesity and acute
cardiovascular events. Cytokine 2010;62(2):210–6.
